Therapeutics
02 March 2010
Centralised patient recruitment company Praxis will provide patient recruitment services to a top 20 pharmaceutical company for an international study on type 2 diabetes. The study explores an investigational drug's effectiveness for maintaining glycemic control for individuals newly diagnosed ...
01 March 2010
Patient recruitment specialist Synexus has recruited 87% of patients for an osteoporosis study for a major biotech, recruiting 494 of the total 565 patients atinternational sites. The trial involved eleven of Synexus' twenty six recruitment centres across the UK, Europe and South Africa. There were ...
04 January 2010
British charity Cancer Research UK is to conduct a Phase I clinical trial of an investigational monoclonal antibody drug, DI-B4, from Merck KGaA (Merck) to target cancer cells which cause non Hodgkin's lymphoma and chronic lymphocytic leukaemia. Under the terms of the partnership, Cancer Research ...
07 December 2009
Psynova Neurotech, a subsidiary of biomarker testing laboratory Rules-Based Medicine (RBM), has begun a research and licensing agreement with Roche to collaborate on the discovery and development of diagnostic immunoassays to aid the clinical development of novel treatments for schizophrenia. ...
 
22 December 2009
Despite their low incidence, fatal cardiac effects such as Torsade de Pointes can cause drugs to be withdrawn from the market. New technologies to assess the possibility of such adverse drug reactions promise to reduce the risk, both to patients and drug companies, but existing legislation has ...
20 August 2009
The heart has always been a major focus of pharmaceutical research. This has produced wave after wave of new revenue streams with therapies that have transformed medical practice and prolonged millions of lives. By 2008, worldwide cardiovascular (CV) sales of US$79.3 billion were second only to ...
 
ACM appoints Asia Pacific manager ACM Global Central Laboratory has appointed a new general manager of Asia Pacific, Nandan Rao , who will spearhead the company's growth in India and Southeast Asia. His first responsibility will be to oversee trials conducted by ACM's partner laboratory, before building the company’s own local ... Venn Life Sciences hires new VP of business development Venn Life Sciences has hired Dale Trask as vice-president of global business development. Mr Trask brings extensive experience in CRO business development and will be responsible for enhancing Venn's business partnerships, strategic relationships and growth into new markets. Mr Trask joins Venn ... Entest Biomedical adds CRO experience to scientific board Entest BioMedical has appointed Dr Vladimir Bogin to its scientific advisory board (SAB). Dr Bogin is the CEO of CRO Cromos Pharma. The company feels the addition of Dr Bogin to the SAB will "greatly assist in developing its clinical protocols as it moves forward to conducting both preclinical and ...
 
The term renal failure describes a decline in the excretory function of the kidney due to a reduction in glomerular filtration rate. In adults, renal failure may be either acute, lasting from a few days to a few weeks, or chronic, lasting months to years. Acute renal failure is a medical ...
Most stakeholders in Europe are in favour of some form of EU centralised approval system for multinational clinical trials, with the pharmaceutical industry and the European Medicines Agency among the strongest backers for such a move. But the support is not unanimous: many national regulatory ...
If you didn't know, how many cases of malaria would you guess occur every year around the globe? A million? Two million? In fact, around 250 million cases of malaria occur each year. Most of these occur in developing countries, although malaria is also an issue for travellers from developed ...
The UK drug regulator, the MHRA, says it does not want a centralised approvals system for clinical trials in Europe, preferring instead the voluntary harmonisation project for authorising multinational studies that is currently being piloted in the EU. The MHRA also feels that introducing a single ...
The problem stems mainly from the way that the EU clinical trials Directive (2001/20/EC) has been implemented by the various member states. National authorities have different format, language and content requirements for clinical trial approvals, as well as different timelines for reviewing ...
The recent announcement by Boehringer Ingelheim that it plans to make the alpha blocker tamsulosin available without a prescription in the UK is a reflection of the continued interest in the benign prostatic hyperplasia (BPH) market. The condition affects some 15 million men across the seven major ...
 
 

EVENTS
17 March 2010
Brussels, Belgium
19 April 2010
London, UK
26 April 2010
London, UK
 
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36